Hypothesis: Different pharmacotherapies for sensorineural hearing loss (SNHL) are interconnected in metabolic networks with molecular hubs. Background: Sensorineural hearing loss is the most common sensory deficit worldwide. Dozens of drugs have shown efficacy against SNHL in animal studies and a few in human studies. Analyzing metabolic networks that interconnect these drugs will point to and prioritize development of new pharmacotherapies for human SNHL. Methods: Drugs that have shown efficacy in treating mammalian SNHL were identified through PubMed literature searches. The drugs were analyzed using the metabolomic analysis and the ''grow-tool function'' in ingenuity pathway analysis (IPA). The top 3 most interconnected molecules and drugs (i.e., the hubs) within the generated networks were considered important targets for the treatment of SNHL.
Sensorineural hearing loss (SNHL) is an etiologically heterogeneous disorder resulting from many genetic and environmental insults (1) . As the most common birth defect in industrialized countries and the most prevalent sensory deficit (2) , SNHL is one of the biggest public health problems. Over 275 million people globally have moderate-to-profound hearing impairment (3) . In the United States alone, the number of people with hearing loss has doubled for the past 30 years, currently affecting approximately 30 million people (4) . With the growing number of individuals affected by this disability, there is a mounting need to develop effective therapies for SNHL.
Over the years, many drugs and compounds have been tested to try to identify pharmacologic agents to treat and prevent SNHL. From here on, we refer to them collectively as ''drugs.'' These drugs include endogenous mammalian chemicals that are part of normal metabolism, such as antioxidants, as well as synthetic chemical drugs, such as dexamethasone. Dozens of the tested drugs have shown some efficacy against SNHL in animals and a few in humans. Despite these efforts, medical therapies for human SNHL are sorely lacking. The molecular pathophysiology underlying different kinds of SNHL is complex, and the number of identified genes related to hearing loss is increasing (1, 5, 6) . A better insight into promising pharmacotherapies for SNHL may be obtained by analyzing molecular networks through which drugs with a known effect on SNHL interact with the body's metabolome. The term metabolome refers to all of the low molecular weight metabolites of biological origin that are present in a biological organism and represent the metabolic status of an organism at the time of a sample collection (7, 8) . The detectable small molecules in a sample may arise from endogenous metabolites and their intermediates, signaling molecules, or exogenous metabolites from the diet, environment, gut microflora, or intake of drugs (7) . Metabolomics refers to the study of some or all of these small molecules.
In this study, we performed metabolomic analysis of the endogenous chemicals used for successful treatment of SNHL in mammals and combined it with a network analysis to include chemical drugs with a significant effect on mammalian SNHL. Network-based analysis, as opposed to traditional, linear, reductionist analysis, is gaining momentum in all biomedical fields (8Y10) because networks provide a more holistic approach to capture the complexity of intracellular and intercellular interactions. The rapidly emerging field of network medicine, which integrates systems biology and network science, promises to transform our understanding of disease etiology, classification, and treatment (10, 11) . The new pharmacologic treatment strategies aspire to capitalize on the understanding of networks to overcome increasing limitations of traditional high-affinity, high-specificity compounds (12) . These evolving strategies reflect our current understanding that many of the key interactions in living systems are of moderate affinities and selectivities, which contributes to the immense flexibility and redundancy of cellular circuits (12) . Therefore, pharmacologic targeting of entire pathways, which reflect sets of well-characterized biochemical reactions inside a cell or an organism (such as Krebs cycle), promises to overcome limitations of compounds that target individual proteins (12, 13) .
To study the existing pharmacotherapies for SNHL within the global environment of interacting molecules and thereby identify most promising compounds and pathways for clinical applications, we used ingenuity pathway analysis (IPA) (Ingenuity Systems, www.ingenuity.com). IPA has been extensively used in biomedical research (having almost 9,000 citations (7)) to analyze big data because its Ingenuity Knowledge Base is the largest curated database of biological and chemical interactions, extracted from the scientific literature (7, 14) . By using IPA's bioinformatics tools to search the knowledge base, we have identified several potential novel molecular targets for the treatment of SNHL and prioritized human testing of drugs that have shown promise in animal studies.
MATERIALS AND METHODS

Literature Review
To identify pharmacotherapies for SNHL tested in mammals, a PubMed English literature search (from January 1960 to August 2012) was performed using the Mesh terms hearing loss, deafness combined with the MESH terms prevention and control, drug, and drug therapy. We considered drugs that improved SNHL, as reflected in lowering of sound level required to elicit auditory brainstem response (ABR) or evoked otoacoustic emissions (OAEs) or decreased loss of hair cells or stereocilia. In the context of noise exposure, drugs that lessened either permanent or temporary threshold shift were considered; permanent threshold shift refers to irreversible increase in ABR thresholds, whereas temporary threshold shift refers to transient increase in ABR thresholds, which returns to normal within 2 to 4 weeks of noise exposure. After elimination of duplicates and articles of unrelated topics, only studies that included control groups with at least 3 subjects and reported a statistically significant difference due to experimental treatment ( p G 0.05) were selected ( Fig. 1 and Table  Supplemental Digital Content 1, http://links.lww.com/MAO/A193, listing drugs used in the analysis, with indication, species, and criteria of efficacy.) With the exception of 1 study (15) , therapeutic benefit ranged from 5-to 50-dB improvement in ABR thresholds or pure tone average and 5% to 50% improvement in hair cell survival.
Metabolomic Analysis
Metabolomic analysis of the drugs identified previously, which are also endogenous mammalian chemicals (Table Supplemen- tal Digital Content 1, http://links.lww.com/MAO/A193), was performed using commercially available IPA (7) . IPA uses the Ingenuity Knowledge Base, which includes millions of measured interactions between genes, proteins, cellular complexes, cells, tissues, drugs, pathways, and diseases, based on published biomedical literature and textbooks. Ingenuity Knowledge Base is the largest curated database, which is updated weekly to include information published as recently as the previous week (7).
We used IPA to map out interactions between drugs implicated in the improvement of SNHL and molecular mechanisms by constructing metabolic networks. Networks are created from ''seed molecules,'' also known as seedsVin our case, the drugs we providedVby IPA searching the knowledge base for molecules that are known to biologically interact with the seeds and connecting these molecules with the seeds. Any 2 molecules that bind, act upon one another, or that are involved with each other in any other manner would be considered connected or linked. The most highly connected seeds and molecules from the knowledge base are consolidated into networks, which graphically represent the regulatory interactions that exist among userspecified seeds, based on characterized interactions within the knowledge base (7) . Within networks, molecules are referred to as nodes, and the biological interaction between two nodes is represented as a line; the line is solid if the interaction is direct and dashed if the interaction is indirect. Direct interactions require that 2 molecules make direct physical contact with each other, without an intermediate step. Indirect interactions do not require a physical contact between the 2 molecules, such as a hormone causing a change in expression of a downstream protein via a signaling cascade (7) . Nodes are displayed using various shapes that represent the functional class of the gene product. The most interconnected molecule (or class of molecules) in a network is considered the hub.
Within IPA, statistical analysis of networks and pathways was conducted with the right-tailed Fisher's exact test. The networks and pathways are scored by significance value, which is a measure of the likelihood that the associations forming the network are due to chance alone (7) . The score is the negative logarithm of the p value, which represents significance. We considered networks with a score greater than 5 (i.e., p G 10 j5 ) to be significant.
A metabolomic analysis of our dataset containing drugs implicated in the improvement of SNHL was performed on September 12, 2012, with IPA version 192063 (fall release). The specific parameters and their justification follow. The reference set was the Ingenuity Knowledge Base version 14197757 (7) . The data sources included all IPA's available data sources from all available species, tissues, and cell lines so to maximize the likelihood of discovering interactions, given the exploratory nature of our analyses. Interactions considered were both direct and indirect not only to capture well-characterized interactions but to also stimulate discovery of novel molecules of likely functional significance, respectively. IPA allows the maximal number of molecules per network to be selected as 35, 70, or 140; we chose 35 to allow the possibility that all drugs that we studied and that were considered metabolites by IPA (i.e., 20 drugs) were a part of a single, small network. An additional advantage of a small metabolic network is that it remains visually tractable even when augmented with 100 additional chemical drugs. Specifically, the IPA networks through a metabolomic analysis can be formed only with ''endogenous mammalian chemicals'' (7), which represent nodes that are linked if they participate in the same biochemical reactions (9) . To add ''chemical drugs'' from our dataset to the metabolic networks, an extra feature of IPA was used: the ''grow tool function'' from ''my pathway'' toolbox. The ''grow tool function'' makes it possible to add new molecules and their interactions, where priority is given to those molecules that, according to the Ingenuity Knowledge Base, have a high degree of connectivity with the other molecules (7). In our case, the chemical drugs with a high degree of connectivity to the molecules in the metabolic networks were added to the networks. An additional network analysis was conducted using the grow tool function only, without starting with a metabolic network first. For this analysis, all pharmacotherapies, including endogenous mammalian chemicals and chemical drugs, were uploaded as independent nodes. These nodes were then linked or connected by growing the network with 100 molecules from the Ingenuity Knowledge Base. IPA calculated which 100 molecules from the knowledge base had the highest degree of connectivity to the drugs from our database to form a network with these drugs.
RESULTS
The literature searches (Fig. 1) identified 135 studies that met our inclusion criteria. These studies generated 85 drugs, 70 of which were present in the Ingenuity Knowledge Base and therefore were eligible for our study. Twenty of the drugs were endogenous mammalian chemicals and the rest were chemical drugs. The drugs were studied for different types of SNHL, including noise-induced hearing loss (NIHL), presbycusis, cisplatin ototoxity, aminoglycoside ototoxity, or unspecified SNHL. The drugs were mostly tested in rodents (guinea pigs, rats, mice, chinchillas, gerbils, or hamsters), and a few were tested in humans (Table Supplemental Digital Metabolomic analysis of the pharmacotherapies for SNHL that consisted of endogenous mammalian chemicals revealed 3 networks. The first two were highly significant ( p = 10 j28 and p = 10 j11 , respectively), whereas the third network did not meet our criterion for significance ( p = 10 j2 ). After growing the top ranking network with the chemical drugs from our database, the resulting network was highly interconnected (Fig. 2) , reflecting the complexity of the underlying molecular and chemical interactions. This complexity can be simplified by focusing on the most interconnected molecules, or hubs, as they are thought to hold the whole network together (16) . The main hub of the top ranking network, which had been augmented with chemical drugs, was P38 mitogen-activated protein kinase (P38 MAPK), having 47 connections or links to other nodes. The subsequent 4 hubs were p44/p42 MAP kinase (ERK) with 45 connections, glutathione with 34 connections, insulin-like growth factor 1 (IGF1) with 27 connections, and activator protein 1 (Ap1) with 26 connections (Table 1 , Fig. 2 and Figure S1 Supplemental Digital Content 2, http://links.lww.com/MAO/A194, showing the most significant network generated by IPA metabolomic analysis of the drugs that ameliorate SNHL and are known to be endogenous mammalian chemicals, augmented with a grow tool to include chemical drugs). After growing the second top ranking metabolic network with the chemical drugs from our database, the top 5 hubs were protein kinase B (Akt) with 54 connections, nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) with 50 connections, p42/44 MAPK (ERK) with 42 connections, insulin with 40 connections, and phosphatidylinositide 3-kinases (PI3K) also with 40 connections (Table 1 and Figure S2 Supplemental Digital Content 3, http://links.lww.com/MAO/A195, showing the second most significant network generated by IPA metabolomics analysis of the drugs that ameliorate SNHL and are known to be endogenous mammalian chemicals, augmented with a grow tool to include chemical drugs).
In addition to networks, which reveal interactions among user-specified molecules, the metabolomic analysis also identified canonical pathways, which are wellestablished cell signaling and metabolic pathways such as the Krebs cycle (6,7). It is remarkable that 4 of 5 top canonical pathways (Table 2 ) discovered by IPA are directly involved with metabolism of retinoic acid, which is a metabolite of vitamin A. Even the remaining pathway, aryl hydrocarbon receptor signaling, has recently been shown to be controlled by all trans retinoic acid (17) , also known as tretinoin, which is the acidic form of vitamin A.
The top 3 most significant biological functions identified through metabolomic analysis were DNA replication, recombination and repair; neurologic disease; and organismal injury and abnormalities. A list of top 20 biological functions is provided in Table 3 .
For network analysis using the grow tool function only to establish connections between all reported pharmacotherapies for SNHL by growing the network with 100 additional molecules, a highly complex network emerged (Table 1 and Figure S3 Supplemental Digital Content 4, http://links.lww.com/MAO/A196, showing the network generated by IPA's grow tool function only to establish connections between all reported pharmacotherapies for SNHL). This network included 62 of the 70 drugs from our database, suggesting substantial interaction among the drugs. By focusing on the hubs of this network, we identify drugs that are most likely to be effective in treating different kinds of SNHL: dexamethasone (61 connections), tretinoin (45 connections), cyclosporin A (40 connections), N-acetyl-L-cysteine (37 connections), and resveratrol (36 connections). The 8 drugs that were not part of the network (i.e., adenosine amine congener, glutathione monoester, acetylcarnitine, trimethadione, D-methadione, ethosuximide, erdosteine, and amifostine) may be acting by distinct molecular mechanisms.
DISCUSSION
A comprehensive metabolomic, network, and pathway analysis of the reported pharmacotherapies for mammalian SNHL has highlighted several molecules and pathways that are attractive targets for development of novel pharmacotherapies for SNHL. These molecules include signaling kinases, such as P38 MAPK, ERK1/2, Akt, and PI3K (Table 1) . Of these, ERK1/2 (which refers to ERK1 and ERK2) is particularly appealing because it was also identified as a key node in our comprehensive network analysis of human deafness genes (6) . We have suggested that mutations in the gene encoding ERK1, known as MAPK1, may account for human nonsyndromic hearing loss at the DFNB40 locus because MAPK1 is located within that locus, which awaits identification of the causative gene (6) . Given that ERK1/2 can signal death or survival of cochlear cells, depending on stimulus (18, 19) , potential therapeutic targeting of ERK1/2 may need to be personalized to avoid toxic side effects. Otology is likely to benefit from and impact oncologicz research (27) Insulin (40) Ap1 (26) PI3K (complex) (40) 2. Network analysis using the grow tool
The molecules in bold were not part of our original data base, whereas the other molecules were.
because of prominent role that ERK plays in pathophysiology of diverse neoplasms and because ERK inhibitors hold chemotherapeutic promise in clinical trials (20) .
Our comprehensive analysis of the reported pharmacotherapies for mammalian SNHL has also prioritized future clinical testing of the drugs that have shown promise in animal studies.
Of these, tretinoin and modulators of vitamin A signaling are especially attractive because tretinoin is not only the second hub in the interactome of the reported pharmacotherapies for SNHL, but retinoic acid signaling also dominates pathway analysis of the 20 endogenous mammalian chemicals with a reported efficacy in alleviating SNHL (Tables 1, 2 ). In line with the modern pharmacologic emphasis on targeting entire pathways, rather than single proteins (12, 13) , our study suggests that pharmacologic targeting of the retinoic acid pathway may be promising in preventing and treating SNHL. Vitamin A is a family of hydrocarbons, which include retinol, retinal, retinoic acid, and several provitamin A carotenoids, such as beta-carotene (21) . Retinoic acid, both all-trans retinoic acid (tretinoin) and 9-cis retinoic acid (alitretinoin), signals via the retinoic acid receptor (RAR). The critical role of retinoic acid signaling for normal development of the inner ear is demonstrated in studies showing that either excess or deficiency in retinoic acid leads to inner ear dysmorphogenesis (22) . Although retinoic acid signaling has not been studied in the adult inner ear, it has been studied in the adult hippocampus where retinoid hyposignaling contributes to age-related decline in memory (23) . A recent prospective study has shown that oral isotretinoin, a drug widely used for treatment of extensive and nodulocystic acne, improved hearing of all 38 treated adults who had both acne and hearing loss (24) . This study, which included shortterm follow-up, combined with our data, strongly motivate future large-scale prospective randomized study to establish long-term efficacy of vitamin A derivatives in alleviating human SNHL; multi-drug targeting of the retinoic acid pathway may be especially promising. As always, drug dosage will need to be precisely defined to assure safety because retinoic acid is known to be teratogenic when used in megadoses, such as required in oncology and dermatology. Localized drug delivery to the inner ear would circumvent potential systemic toxicity.
It is reassuring that dexamethasone, a potent synthetic glucocorticoid, has emerged as the central node within the interactome of reported pharmacotherapies for mammalian SNHL, given the well-documented therapeutic effect of intratympanic dexamethasone in alleviating sudden SNHL in humans. The marked interconnectedness of dexamethasone is not surprising because dexamethasone is known to greatly change the global expression profiles of genes and microRNA in various tissues, including the inner ear (25Y27). The prominence of another immunosuppressive drug, cyclosporine A, and the emergence of the proinflammatory transcription factor NFkB as a major node in our metabolomic analysis highlight therapeutic significance of controlling inflammation to prevent hearing loss.
The methodology we have introduced has important implication for the development of novel pharmacotherapies for SNHL. Given the significant overlap between processes that govern SNHL responsiveness to drugs, and diverse processes such as dementia, cardiovascular disease, and lipid metabolism (Table 3) , otologic patients may benefit from the drugs originally developed for other indications. Indeed, a systems-level exploration of offtarget drug effects is gaining momentum not only to understand side-effect profiles of the various drugs but also to discover potent and unexpected therapeutic targets for drug repurposing (28, 29) .
A shortcoming of our approach is that it is inevitably biased by the most extensively studied molecules and molecular interactions, which dominate the biomedical literature across fields and hence dominate the bioinformatic knowledge base. In addition, our analyses are constrained in time because the knowledge base is continuously evolving to reflect the latest discoveries from the literature. Nonetheless, our study outlines a networkbased approach to systematizing the literature on pharmacotherapies for SNHL, which can be reapplied as the knowledge base expands. The network-based approach provides a new insight into and prioritizes testing of the most promising pharmacologic strategies for future prospective randomized clinical trials. 
CONCLUSION
We provide the first metabolomic and network analysis of pharmacotherapies for SNHL. By studying molecular interconnectedness between the reported pharmacotherapies for SNHL, which were largely studied in animal models, we define and prioritize potential novel targets and pharmacotherapies for human SNHL. Our analyses suggest that modulation of inner-ear signaling via ERK1/2 and vitamin A, either alone or in combination with therapies targeting inflammation, are promising strategies for future prospective randomized clinical trials for SNHL.
